

Clinical trials of policosanol

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
policosanol vs control			
Batista , 1996 n=15/14 follow-up: 1.7 years	-	-	Parallel groups
Castano , 2001 n=27/29 follow-up: 2 years	policosanol 10 mg twice daily versus placebo	intermittent claudication	Parallel groups double-blind
Ms , 1999 n=219/218 follow-up: 24 weeks	policosanol 5mg titrted up for 10mg daily versus placebo	patients with type II hypercholesterolemia and additional coronary risk factors	Parallel groups double-blind

└ More details and results :

- cholesterol lowering intervention for cardiovascular prevention in patients with other atherosclerotic localisation at <http://www.trialresultscenter.org/go-Q126>
- cholesterol lowering intervention for cardiovascular prevention in all chronical situations at <http://www.trialresultscenter.org/go-Q154>

References

Batista, 1996:

Batista JF, Stsser RJ, Padrn R, Sosa F, Pereztol O, Prez B.P Functional Improvement in Coronary Artery Disease After 20 months of Lipid-Lowering Therapy with Policosanoly

Advances in Therapy. 1996;13:137-148imag

Castano, 2001:

Castao G, Ms Ferreira R, Fernndez L, Gmez R, Illnait J, Fernndez C A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52:115-25 [[11228084](#)]

Ms, 1999:

Ms R, Castao G, Illnait J, Fernndez L, Fernndez J, Alemn C, Pontigas V, Lescay M Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65:439-47 [[10223782](#)]